Evaluting the therapeutic and adverse effects of Interferon beta 1-a in patients with novel Coronavirus(COVID-19)
Phase 3
- Conditions
- COVID-19 pneumonia.Coronavirus infection, unspecifiedB34.2
- Registration Number
- IRCT20151227025726N12
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Laboratory confirmed COVID-19 with RT-PCR
Respiratory rate > 30/min
Oxygen saturation < 90%
PaO2/FiO2 < 300mmHg
Exclusion Criteria
Chronic kidney Disease
Pregnancy or breastfeeding
Drug allergy history
Pneumonia due to influenza virus, bacterial pneumonia, fungal pneumonia, and noninfectious causes
Chronic liver disease
Acute kidney injury
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical response to therapy. Timepoint: Daily. Method of measurement: Clinical symptoms.
- Secondary Outcome Measures
Name Time Method Hospitalization duration. Timepoint: At admission time and discharge time. Method of measurement: Clinical records.;Lung radiology changes. Timepoint: At admission time and seven and 14 days later. Method of measurement: Computed tomography.;Adverse Drug Reaction. Timepoint: Daily. Method of measurement: Observation.